Who owns Brainstorm Cell Therapeutics?
- Ticker: BCLI
- CUSIP Number: 10501e201
Tip: Access positions for across all investors
Analyze quarterly positions in Brainstorm Cell Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Brainstorm Cell Therapeutics stock
Who bought or sold Brainstorm Cell Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Vanguard Group | 1.4M | $791k | -2% | Mar 2024 |
|
| BlackRock | 489k | $276k | 5% | Mar 2024 |
|
| Geode Capital Management | 357k | $202k | 15% | Mar 2024 |
|
| Liberty Wealth Management | 340k | $192k | 0% | Mar 2024 |
|
| Weaver Consulting Group | 199k | $113k | -5% | Mar 2024 |
|
| Caldwell Sutter Capital | 157k | $0 | 0% | Mar 2024 |
|
| Abner, Herrman & BrocK | 146k | $82k | 0% | Mar 2024 |
|
| Raymond James & Associates | 114k | $64k | -2% | Mar 2024 |
|
| GSA Capital Partners | 111k | $63k | 100% | Mar 2024 |
|
| Ikarian Capital | 90k | $51k | 0% | Mar 2024 |
|
| Kingswood Wealth Advisors | 81k | $46k | 100% | Mar 2024 |
|
| Virtu Financial | 71k | $19k | 100% | Dec 2023 |
|
| Jmac Enterprises | 65k | $37k | 0% | Mar 2024 |
|
| Northern Trust | 55k | $31k | 0% | Mar 2024 |
|
| Citadel Advisors | 51k | $29k | -33% | Mar 2024 |
|
| Morgan Stanley | 40k | $23k | 31% | Mar 2024 |
|
| Susquehanna International | 39k | $22k | 60% | Mar 2024 |
|
| Group One Trading | 31k | $17k | -68% | Mar 2024 |
|
| Wells Fargo & Company | 29k | $17k | -3% | Mar 2024 |
|
| Creative Planning | 22k | $12k | 3% | Mar 2024 |
|
| Saxony Capital Management | 21k | $12k | -1% | Mar 2024 |
|
| Janney Montgomery Scott | 21k | $12k | 0% | Mar 2024 |
|
| Jane Street | 19k | $11k | 100% | Mar 2024 |
|
| Professional Financial Advisors | 17k | $9.8k | 0% | Mar 2024 |
|
| First Affirmative Financial Network | 15k | $8.6k | -3% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 13k | $7.2k | 0% | Mar 2024 |
|
| Socha Financial Group | 12k | $7.0k | 0% | Mar 2024 |
|
| Bank of New York Mellon | 12k | $6.8k | 0% | Mar 2024 |
|
| Tower Research Capital | 11k | $6.2k | -72% | Mar 2024 |
|
| Advisor Group Holdings | 11k | $5.9k | -2% | Mar 2024 |
|
| Cypress Capital Management | 10k | $5.6k | 0% | Mar 2024 |
|
| Institutional & Family Asset Management | 6.0k | $3.4k | 0% | Mar 2024 |
|
| Steward Partners Investment Advisory | 4.2k | $2.4k | 0% | Mar 2024 |
|
| Simplex Trading | 4.0k | $2.0k | 100% | Mar 2024 |
|
| Bangor Savings Bank | 4.0k | $2.3k | 0% | Mar 2024 |
|
| UBS Group | 2.5k | $1.4k | 0% | Mar 2024 |
|
| EverSource Wealth Advisors | 2.1k | $580.944000 | 0% | Mar 2024 |
|
| VisionPoint Advisory Group | 1.9k | $1.1k | 0% | Mar 2024 |
|
| Able Wealth Management | 1.9k | $523.968000 | 100% | Dec 2023 |
|
| Cranbrook Wealth Management | 1.0k | $565.000000 | 100% | Mar 2024 |
|
| Bank of America Corporation | 1.0k | $564.000000 | -5% | Mar 2024 |
|
| D. J. St. Germain | 500.00 | $137.000000 | 0% | Dec 2023 |
|
| Bnp Paribas Arbitrage, Snc | 364.00 | $205.987600 | 0% | Mar 2024 |
|
| Royal Bank of Canada | 317.00 | $0 | -42% | Mar 2024 |
|
| Westside Investment Management | 200.00 | $112.000000 | 0% | Mar 2024 |
|
| Jpmorgan Chase & Co | 106.00 | $59.996000 | 49% | Mar 2024 |
|
| Mark Sheptoff Financial Planning | 100.00 | $56.000000 | 0% | Mar 2024 |
|
Who sold out of Brainstorm Cell Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| ADAR1 Capital Management | Dec 2023 | 101k | $28k |
| Barclays | Dec 2023 | 46k | $12k |
| LPL Financial | Sep 2023 | 41k | $8.3k |
| XTX Topco | Sep 2023 | 25k | $4.9k |
| Zullo Investment Group | Dec 2023 | 16k | $4.4k |
| HighTower Advisors | Dec 2023 | 10k | $3.0k |
| Harbour Investments | Sep 2023 | 796.00 | $158.961200 |